PYC Therapeutics (ASX:PYC) Releases Q2 2025 Shareholder Update
PYC Therapeutics (ASX:PYC) updates shareholders on significant clinical progress and a strong financial position in Q2 2025.
PYC Therapeutics (ASX:PYC) updates shareholders on significant clinical progress and a strong financial position in Q2 2025.
G8 Education Limited (ASX:GEM) addresses ASX’s aware letters concerning an employee charge and subsequent stock price decline.
Imugene Limited (ASX:IMU) reports 75% response rate in Phase 1b trial of azer-cel for relapsed diffuse large B-cell lymphoma.
Orthocell (ASX:OCC) records first US sales revenue from Remplirâ„¢ nerve repair product, marking a significant milestone in US expansion.
Resolution Minerals (ASX:RML) secures drilling permits for Horse Heaven Project and progresses acquisition, with drilling set to begin in August 2025.
Wrkr Ltd (ASX:WRK) extends its partnership with MUFG Retirement Solutions to deliver a new digital platform for AustralianSuper, enhancing superannuation services.
Australian Pacific Coal Limited (ASX:AQC) suspends ASX trading pending updates on Dartbrook Mine operations and financial assessments.
Ionic Rare Earths Limited (ASX:IXR) responds to ASX’s price query, citing recent operational updates and a $3m capital raise as factors behind trading activity.
Argosy Minerals (ASX:AGY) requests a trading halt pending a capital raising announcement, effective until July 8, 2025.
Capricorn Metals Limited (ASX:CMM) reports Q4 gold production of 32,216 ounces, meeting annual guidance and advancing expansion projects.